These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34858498)

  • 1. Enhancing the Therapeutic Efficacy of KRAS
    Liu Y; Wu L; Lu H; Wu E; Ni J; Zhou X
    J Oncol; 2021; 2021():2721466. PubMed ID: 34858498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS
    Ryan MB; Fece de la Cruz F; Phat S; Myers DT; Wong E; Shahzade HA; Hong CB; Corcoran RB
    Clin Cancer Res; 2020 Apr; 26(7):1633-1643. PubMed ID: 31776128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS
    Ryan MB; Coker O; Sorokin A; Fella K; Barnes H; Wong E; Kanikarla P; Gao F; Zhang Y; Zhou L; Kopetz S; Corcoran RB
    Cell Rep; 2022 Jun; 39(12):110993. PubMed ID: 35732135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to KRAS
    Blaquier JB; Cardona AF; Recondo G
    Front Oncol; 2021; 11():787585. PubMed ID: 35004309
    [No Abstract]   [Full Text] [Related]  

  • 5. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
    Misale S; Fatherree JP; Cortez E; Li C; Bilton S; Timonina D; Myers DT; Lee D; Gomez-Caraballo M; Greenberg M; Nangia V; Greninger P; Egan RK; McClanaghan J; Stein GT; Murchie E; Zarrinkar PP; Janes MR; Li LS; Liu Y; Hata AN; Benes CH
    Clin Cancer Res; 2019 Jan; 25(2):796-807. PubMed ID: 30327306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
    Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
    Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PI3Kα overcomes resistance to KRas
    Qi WL; Li HY; Wang Y; Xu L; Deng JT; Zhang X; Wang YX; Meng LH
    Acta Pharmacol Sin; 2023 May; 44(5):1083-1094. PubMed ID: 36411339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
    Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
    Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS G12C inhibitor combination therapies: current evidence and challenge.
    Miyashita H; Kato S; Hong DS
    Front Oncol; 2024; 14():1380584. PubMed ID: 38756650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting ST8SIA6-AS1 counteracts KRAS
    Wang Y; Yao M; Li C; Yang K; Qin X; Xu L; Shi S; Yu C; Meng X; Xie C
    Exp Hematol Oncol; 2023 Dec; 12(1):105. PubMed ID: 38104151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer.
    Miyashita H; Hong DS
    J Cancer Immunol (Wilmington); 2024; 6(2):62-69. PubMed ID: 39175850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 mediates clinical resistance to the KRAS
    Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
    Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Breakthrough Brought about by Targeting KRAS
    Ning W; Yang Z; Kocher GJ; Dorn P; Peng RW
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined KRAS
    Thatikonda V; Lu H; Jurado S; Kostyrko K; Bristow CA; Bosch K; Feng N; Gao S; Gerlach D; Gmachl M; Lieb S; Jeschko A; Machado AA; Marszalek ED; Mahendra M; Jaeger PA; Sorokin A; Strauss S; Trapani F; Kopetz S; Vellano CP; Petronczki M; Kraut N; Heffernan TP; Marszalek JR; Pearson M; Waizenegger I; Hofmann MH
    bioRxiv; 2023 Jan; ():. PubMed ID: 36747713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
    Lu H; Liu C; Velazquez R; Wang H; Dunkl LM; Kazic-Legueux M; Haberkorn A; Billy E; Manchado E; Brachmann SM; Moody SE; Engelman JA; Hammerman PS; Caponigro G; Mohseni M; Hao HX
    Mol Cancer Ther; 2019 Jul; 18(7):1323-1334. PubMed ID: 31068384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covalent inhibitor targets KRas
    Li HY; Qi WL; Wang YX; Meng LH
    Genes Dis; 2023 Mar; 10(2):403-414. PubMed ID: 37223497
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery of highly potent and selective KRAS
    Yang N; Fan Z; Sun S; Hu X; Mao Y; Jia C; Cai X; Xu T; Li B; Li Y; Han L; Wei T; Qian X; Qin W; Li P; Zheng Z; Li S
    Eur J Med Chem; 2023 Dec; 261():115857. PubMed ID: 37852032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition.
    Tsai YS; Woodcock MG; Azam SH; Thorne LB; Kanchi KL; Parker JS; Vincent BG; Pecot CV
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 34990404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.